within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03A_LowCeilingDiureticsThiazides.C03AB01_BendroflumethiazideAndPotassium;
model BendroflumethiazideAndPotassium 
   extends Pharmacolibrary.Drugs.ATC.C.C03AB01;

  annotation(Documentation(
    info ="<html><body><p>Bendroflumethiazide is a thiazide diuretic used in the management of hypertension and edema, commonly in combination with potassium to minimize the risk of hypokalemia. The combination is indicated to help maintain potassium balance during diuretic therapy. It is approved and used in clinical practice, especially for hypertension and conditions causing fluid overload.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adults for oral administration of bendroflumethiazide component, as direct published data for the fixed combination with potassium are lacking.</p><h4>References</h4><ol><li><p>Borgström, L, et al., &amp; Lenander, R (1981). Pharmacokinetics of bendroflumethiazide after low oral doses. <i>Journal of pharmacokinetics and biopharmaceutics</i> 9(4) 431–441. DOI:<a href=&quot;https://doi.org/10.1007/BF01060887&quot;>10.1007/BF01060887</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7310642/&quot;>https://pubmed.ncbi.nlm.nih.gov/7310642</a></p></li><li><p>Vergin, H, et al., &amp; Strobel, K (1986). [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone]. <i>Arzneimittel-Forschung</i> 36(3) 490–495. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3707669/&quot;>https://pubmed.ncbi.nlm.nih.gov/3707669</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end BendroflumethiazideAndPotassium;
